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Abstract
Background—The GABAergic neuroactive steroid (3α,5α)-3-hydroxy-pregnan-20-one (3α,5α-
THP, allopregnanolone) enhances GABAergic activity and produces subjective effects similar to 
ethanol. The effect of chronic alcohol exposure on 3α,5α-THP concentrations has been studied in 
mouse, rat, and monkey limbic brain areas. Chronic ethanol exposure produced divergent brain 
region and cell specific changes in 3α,5α-THP concentrations in animal studies. However, 3α,5α-
THP levels in similar human brain regions have never been examined in individuals diagnosed 
with alcohol use disorder (AUD). Therefore, we used immunohistochemistry to examine 3α,5α-
THP levels in the ventral tegmental area (VTA), substantia nigra pars medialis (SNM), and 
amygdala of human postmortem brains of patients diagnosed with AUD compared to social 
drinkers. The effects of sex and liver disease on 3α,5α-THP concentrations were examined in the 
aforementioned brain regions.
Methods—Human postmortem brains of AUD patients and age-matched controls were obtained 
from the New South Wales Brain Tissue Resource Center. Immunohistochemistry was performed 
using anti-3α,5α-THP antibody on formalin fixed and paraffin embedded brain sections to detect 
cellular 3α,5α-THP levels. Immunoreactivity was analyzed by pixel density/mm2 for the 
comparison between AUD patients and controls.
Results—3α,5α-THP immunoreactivity was increased by 23.2±9% in the VTA of AUD patients 
compared to age matched controls (p= 0.014). Moreover, a 29.6±10% increase in 3α,5α-THP 
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immunoreactivity was observed in the SNM of male AUD patients compared to male controls 
(p<0.01), but not in female subjects. 3α,5α-THP immunoreactivity in the VTA and SNM regions 
did not differ between non-cirrhotic and cirrhotic AUD patients. A sex difference in 3α,5α-THP 
immunoreactivity (female 51±18% greater than male) was observed among control subjects in the 
SNM, but no other brain region. 3α,5α-THP immunoreactivity in the basolateral and lateral 
amygdala were negatively correlated with the length of the tissue fixation time as well as the age 
of the subjects, precluding assessment of the effect of AUD.
Conclusions—Cellular 3α,5α-THP levels in VTA are increased in human AUD patients, an 
effect that is likely independent of sex and liver disease. The differences between animal models 
and human studies should be factored into the interpretation of the physiological significance of 
elevated 3α,5α-THP levels in humans.
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Introduction
Alcohol Use Disorder (AUD) is a chronic relapsing disorder that is one of the leading causes 
of lost human potential worldwide. A major goal of basic research on AUD is to understand 
the transition from alcohol use to alcohol dependence by revealing changes in 
neurotransmitter systems (Tabakoff and Hoffman, 2013). The Ɣ-aminobutyric acid type A 
(GABAA) receptors contribute to the behavioral effects of ethanol and play central roles in 
the short and long term effects of alcohol (Kumar et al., 2009). The function of GABAA 
receptors is modulated by potent endogenous neuroactive steroids that are produced in the 
brain, adrenal glands, and gonads (Gunn et al., 2015).
The GABAergic neuroactive steroids function as positive allosteric modulators of GABAA 
receptors, enhancing GABAergic function at nanomolar concentrations (Morrow et al., 
1987). GABAergic neuroactive steroids act through specific binding sites on the α subunits 
to increase GABAA receptor activity to produce effects pharmacologically similar to ethanol 
(Hosie et al., 2006). Systemic administration of GABAergic neuroactive steroids exerts 
pharmacological responses including anxiolytic, antidepressant, anticonvulsant, sedative, 
and anesthetic effects in animal models and human studies that reflect their actions on 
GABAA receptors (Belelli et al., 1989, Bitran et al., 1991, Khisti et al., 2000, Hogskilde et 
al., 1987).
The effects of ethanol involve several GABAergic mechanisms that contribute to many of its 
behavioral actions. (3α,5α)-3-hydoxy-pregnane-20-one (3α,5α-THP or allopregnanolone) is 
one of the most potent GABAergic steroids and has been frequently studied in alcohol 
research. Ethanol increases de novo synthesis of 3α,5α-THP in rat brain (VanDoren et al., 
2000), likely contributing to the changes in the GABAA receptor function. Moreover, 
neuroactive steroids contribute to alcohol sensitivity and may influence the risk of AUD 
(Morrow et al., 2006, Porcu and Morrow, 2014). Increasing evidence suggests that 3α,5α-
THP, like ethanol, plays a role in modulating plastic changes on GABAA receptors (Concas 
et al., 1998, Follesa et al., 2000, Follesa et al., 2006). Taken together, brain 3α,5α-THP 
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levels are involved in various mechanisms of alcohol related effects in central nervous 
system.
Recent studies elucidated the connection between chronic ethanol exposure and brain 3α,
5α-THP levels. Studies in animals have shown that 17 days of voluntary ethanol drinking 
under limited access conditions produced a 1.65 fold increase in whole brain 3α,5α-THP 
concentration in male C57BL/6J mice, but not in the female mice (Finn et al., 2004). High 
levels of ethanol consumed in liquid diet for 14 days produced a small decrease in cortical 
3α,5α-THP levels in male ethanol-dependent rats, but not in the female rats, while cortical 
3α,5α-THP levels did not differ in ethanol withdrawn rats vs. controls (Janis et al., 1998). 
Similarly, 2 month daily intragastric ethanol administration and withdrawal decreased 3α,
5α-THP content measured by gas chromatography-mass spectroscopy in cerebral cortex and 
hippocampus in Sprague Dawley rats (Cagetti et al., 2004). Recent studies using 
immunohistochemistry showed that intermittent ethanol exposure and withdrawal over 4 
weeks decreases cellular 3α,5α-THP levels in the medial prefrontal cortex, ventral 
tegmental area, nucleus accumbens core, lateral amygdala, central nucleus of the amygdala, 
and dorsolateral striatum in C57BL/6J mice, but increases 3α,5α-THP levels in the CA3 
pyramidal cell layer of the hippocampus, and does not alter 3α,5α-THP levels in several 
other limbic brain regions (Maldonado-Devincci et al., 2014). In cynomolgus monkeys, 12 
months of voluntary ethanol consumption decreases 3α,5α-THP levels in lateral and 
basolateral amygdala where 3α,5α-THP immunoreactivity densities were negatively 
correlated with average daily drinking (Beattie et al., 2015). These animal studies have 
shown that ethanol produces divergent brain and cell specific changes in 3α,5α-THP 
concentrations which can differ across species.
The role 3α,5α-THP in alcohol actions in humans have been examined in only a few 
studies, primarily sampling human blood. Human male and female adolescents seen in the 
emergency room for alcohol intoxication had elevated 3α,5α-THP plasma levels (Torres and 
Ortega, 2003, Torres and Ortega, 2004). In contrast, ingestion of 3 standard drinks over 1 
hour failed to alter plasma 3α,5α-THP or other GABAergic neurosteroid levels in laboratory 
settings (Holdstock et al., 2006, Porcu et al., 2010, Pierucci-Lagha et al., 2006), suggesting 
that alcohol dose might be a key factor. In addition, pretreatment with the 
neurosteroidogenic enzyme inhibitors finasteride and dutasteride reduced the subjective 
effects of acute alcohol administration in humans (Pierucci-Lagha et al., 2005, Covault et al., 
2014). Studies on human AUD patients have shown that plasma 3α,5α-THP levels are 
decreased in early alcohol withdrawal and returned to normal levels upon recovery (Romeo 
et al., 1996). Recently, a study sampling postmortem human tissue has shown that 
pregnenolone (a precursor to 3α,5α-THP) and dehydroepiandrosterone (DHEA, a precursor 
of the GABAergic steroid androsterone) levels were higher in several limbic brain areas of 
AUD patients compared to non-alcoholic controls, although testosterone levels were similar 
in the same regions across groups (Karkkainen et al., 2016). To our knowledge, this is the 
first study of brain 3α,5α-THP levels in human AUD patients.
The ventral tegmental area (VTA) is part of the mesolimbic pathway, and is strongly 
implicated in ethanol reinforcement (McBride et al., 1999). Recently, our lab has shown that 
viral vector mediated over-expression of the P450scc enzyme, the rate limiting 
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mitochondrial enzyme initiating steroidogenesis, causes an increase in 3α,5α-THP 
immunoreactivity in the VTA and reduces operant ethanol self-administration in rats (Cook 
et al., 2014b), suggesting that 3α,5α-THP levels in the VTA may regulate ethanol drinking. 
Furthermore, chronic intermittent ethanol exposure reduced 3α,5α-THP immunoreactivity 
in VTA of C57BL/6J mice (Maldonado-Devincci et al., 2014). The substantia nigra is part of 
the midbrain dopamine system, and provides dopaminergic tone necessary for voluntary 
movement (Bissonette and Roesch, 2016). Pars medialis substantia nigra (SNM) is located 
in the ventromedial aspect of the substantia nigra pars compacta (SNC) (Halliday, 2012), 
next to the VTA. Recent findings suggest that dopaminergic neurons in the SNC may also 
play a role in reward prediction processes (Matsumoto and Hikosaka, 2009) and ethanol 
consumption (Kim et al., 2015). Dopaminergic neurons in the ventromedial region in the 
SNC and VTA primarily project to the ventral striatum and transfer information related to 
reward values (Matsumoto and Hikosaka, 2009, Nomoto et al., 2010). The amygdala is a 
brain region that affects multiple aspects of human behavior, including anxiety (Gilpin et al., 
2015) and alcohol seeking (Chaudhri et al., 2013). Long-term ethanol exposure has been 
shown to alter 3α,5α-THP levels in the amygdala subregions studied in mice (Maldonado-
Devincci et al., 2014) and monkeys (Beattie et al., 2015). The present study examined the 




Formalin fixed paraffin embedded (FFPE) human postmortem brain sections from 38 AUD 
patients and 27 control cases were obtained from the New South Wales Brain Tissue 
Resource Center (NSWBTRC) at the University of Sydney in Australia. Clinical information 
regarding subjects was provided by NSWBTRC, including age, sex, cause of death, smoking 
history, liver pathology, lifetime alcohol consumption (kg), average daily ethanol intake (g), 
and total drinking years. Diagnostic and Statistical Manual of Mental Disorders (4th ed.; 
DSM-IV; American Psychiatric Association, 1994) criteria were used to diagnose patients 
for AUD. Comorbidity with neurologic, psychiatric, and neurodegenerative disorders were 
the exclusion criteria for this study to eliminate confounding factors. Sex, age, alcohol 
consumption rate, postmortem interval, and lengths of the tissue fixation time in AUD 
patients and control subjects are reported in Table 1. Cardiovascular and respiratory system 
related complications were the most common causes of death for the AUD patients (58%) 
and control cases (87%).
Pathological information regarding postmortem human samples was provided by 
NSWBTRC, including brain pH, post-mortem interval, and length of tissue fixation time 
(Table 1.). The mean brain pH was 6.5±0.1 for all groups. Length of tissue fixation time 
varied between brain regions that are included in the study. The average fixation time for 
VTA and SNM regions, which are located in human midbrain, averaged 23.5±1 days. 
However, human amygdala samples were stored in formalin for 6±1 years.
Effect of the liver status was examined to determine if liver pathology contributed to the 
effect of AUD on 3α,5α-THP immunoreactivity. Autopsy information of pathological 
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changes were categorized as normal liver, congestion, mild or moderate steatosis (fatty 
liver), and cirrhosis. Among AUD patients, 55% of the subjects were complicated with liver 
cirrhosis, 40% of the subjects had congestion or mild to moderate steatosis, and only 5% of 
the subjects had normal liver. In comparison, 60% of the control cases had no liver 
pathology (normal liver), while 40% of the control cases had mild congestion or mild liver 
steatosis. None of the control subjects had liver cirrhosis.
Immunohistochemistry (IHC)
IHC was performed on FFPE brain slides using a procedure modified from rat brain (Cook 
et al., 2014a) to detect cellular 3α,5α-THP levels. Slides were deparaffinized with xylene, 
rehydrated with gradually decreasing ethanol concentrations, and rinsed in phosphate 
buffered saline (PBS) at pH 7.4. After rinsing, tissues were incubated in 0.6% H2O2 to block 
endogenous peroxidase activity. Antigen retrieval was performed using 10X Citra Plus 
buffer (BioGenex, Fremont, CA) at pH 6.0 at 100 °C for 30 min. This was followed by 
rinsing in PBS. Slides were then blocked for 1 hr with 10% rabbit serum (Vector 
Laboratories, Burlingame, CA) and incubated in the sheep affinity-purified anti-3α,5α-THP 
primary antibody (purchased from Dr. R.H. Purdy) in 1:2500 dilution for 48 hr at 4°C. Next, 
sections were rinsed in PBS, and followed by incubation in a rabbit anti-sheep biotinylated 
secondary antibody (Vector Laboratories, Burlingame, CA) for 60 min. Avidin-biotin 
amplification was performed with Vectastain Elite ABC Kit (Vector Laboratories), and 
immunoreactivity was visualized with nickel enhanced 3,3’-diaminobenzidine (Sigma-
Aldrich, St. Louis, MO) based on manufacturers’ recommended protocol. Tissue was then 
dehydrated with gradually increasing ethanol concentrations and cleaned with xylene. 
Sections were cover slipped with Cytoseal XYL (Richard-Allen Scientific, Kalamazoo, MI) 
mounting media and sealed.
Anatomical Delineation
The term “ventral tegmental area (VTA)” has been used to refer to a collective name for 
parabranchial pigmented nucleus (PBP), paranigral nucleus (PN), parapeduncular nucleus 
(PaP), interfascicular nucleus (IF), rostral linear nucleus of the raphe (RLi), and caudal 
linear nucleus of the raphe (CLi) (Halliday and Tork, 1986, Halliday, 2012). VTA is also 
described as a nucleus, which is found at the ventromedial aspect of the red nucleus and is 
situated medial to the PBP in the transverse plane (McRitchie et al., 1996, Halliday, 2012, 
Reyes et al., 2012). We adopted this definition of the VTA nucleus term for this study (see 
Figure 1).
The ventromedial aspect of the substantia nigra, known as the substantia nigra pars medialis 
(SNM), is located ventrolateral to the red nucleus and is found next to the VTA in the rostro-
caudal transverse sections (McRitchie et al., 1996, Halliday, 2012). VTA and SNM were 
sectioned in the transverse plane and examined simultaneously in the midbrain. Human 
amygdala slides were sectioned and examined in the coronal plane. Atlases of the human 
brain were used to identify anatomical boundaries and denomination of the sub regions of 
the amygdaloid complex (Mai et al., 2008).
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Brain region immunoreactivity was visualized with an Olympus CX51 light microscope 
(Olympus America, Center Valley, PA, USA); images were captured with a digital camera 
(Regita model; QImaging, Burnaby, BC, Canada) and analyzed using Bioquant (Nashville, 
TN, USA) image analysis to obtain linear integrated optical density. The microscope, 
camera, and software were background corrected to eliminate non-specific labeling and 
normalized to preset light levels to ensure fidelity of the data acquisition. Immunoreactivity 
was quantified by pixel density/mm2 from a circumscribed field, delineated as a brain 
region, divided by the area of the region in square millimeters. Additionally, positive cell 
count measurements were calculated from a defined region, divided by the area of the region 
in square millimeters (cell count/mm2). Cell count analysis yielded similar results to pixel 
density/mm2 analysis, suggesting that changes in the number of positive cells are a major 
component of pixel density analysis (data not shown). However, cell count data can be 
inaccurate when cells overlap in the field of analysis, usually leading to underestimation of 
the number of cells. Therefore, the results were only reported as pixel density/mm2 to 
maximize accuracy and avoid duplication of the data. Data from 4 sequential sections per 
subject from a single hemisphere were used to average a single value per region. Three 
comparable regions in lateral amygdala, 2 comparable regions in basolateral amygdala, and 
1 comparable region in VTA and SNM were analyzed under 4x magnification to average a 
single value per subject. The experimenter was blind to the condition of each subject when 
analyses were conducted.
Double Immunofluorescent Labeling of 3α,5α-THP with NeuN and TH
Double immunofluorescent labeling and confocal microscopy was performed on FFPE brain 
slides to detect cell types that exhibit 3α,5α-THP positive immunostaining. After 
deparaffinization and rehydration, antigen retrieval was performed using 10X Citra Plus 
buffer at pH 6.0 at 100 °C for 15 min. Slides were then rinsed in PBS and blocked for 1 hr 
with 10% donkey serum (Jackson Immunoresearch Labs Inc., West Grove, PA) and 
incubated in primary antibody for cell type specific markers: TH (1:1000; ImmunoStar) or 
NeuN (1:1000, (D4G40) XP, Cell Signaling Technologies) for 24 hr at 4°C. Next, slides 
were rinsed, blocked, and incubated with anti-3α,5α-THP primary antibody for 48 hr at 
4°C. Then, sections were rinsed and incubated with secondary antibody (Alexa Fluor 488 for 
3α,5α-THP visualization and Alexa Fluor 594 for cell-type specific markers; Life 
Technologies). Immunofluorescence was visualized using a Leica SP2 laser scanning 
confocal microscope and computer software.
3α,5α-THP Antibody
The anti-3α,5α-THP antibody used for these studies was previously described (Cook et al., 
2014). We observed cross reactivity with 3α-hydroxy-4-pregnen-20-one (3α-HP; 
41±0.14%), (3α,5β)-3-hydroxypregnan-20-one (3α,5β-THP; 22±0.43%), progesterone 
(14±1.95%), 3α,5α-THDOC (11±0.29%), and pregnenolone (9±1.61%). In the present 
study, we tested for cross reactivity with the GABAergic metabolites of testosterone and 
DHEA by radioimmunoassay (RIA). Standards of 3α,5α-THP, 3α,5α-androstandiol, 3α,5β-
androstandiol, 3α,5α-androsterone, and 3α,5β-androsterone were diluted in 95% EtOH at 
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an initial concentration of 100 μg/ml. RIAs were repeated twice for each compound, 
following previously described methods (Janis et al., 1998, Cook et al., 2014a). Briefly, 5 μl 
of each concentration of the steroids (14 concentrations, 40 – 0.0049 ng/ml) was mixed with 
10,000 counts per minute of [3H]3α,5α-THP, and a 1:500 dilution of the affinity purified 
antiserum. Unbound [3H]3α,5α-THP was removed by centrifugation after adding dextran-
coated charcoal. The supernatant was mixed with Ecoscint H (National Diagnostics, Atlanta, 
GA) and [3H]3α,5α-THP was measured in a scintillation counter. The resulting curves were 
analyzed using a one-site competition model (Prism; GraphPad Software, La Jolla, CA) for 
EC50 values. We observed minimal cross-reactivity with 3α,5α-androstandiol (1.13%), 3α,
5β-androstandiol (1.3E-06%), 3α,5α-androsterone (0.85%), and 3α,5β-androsterone 
(0.66%).
Statistical analysis
Raw pixel densities (average pixels/mm2) were analyzed in amygdala sections and used for 
direct comparison. Due to large sample sizes of human midbrain sections (VTA and SNM), 
immunostaining was performed in sequential assays. Data from each assay were 
transformed to percent of control (individual mean/[control group mean]*100) values, and 
compared statistically between groups. Student's t tests (Prism; Graphpad software) were 
used to compare 3α,5α-THP levels from control subjects and AUD patients. Pearson's 
correlation was used to determine the association between lifetime total alcohol drinking 
(kg) and mean alcohol consumption per day with 3α,5α-THP immunoreactivity. Analysis of 
variance (ANOVA) was used to determine the effects of sex, liver status, and smoking status 
on 3α,5α-THP immunoreactivity. Pearson's correlation and linear regression analysis were 
performed to determine the effect of age, postmortem interval, and the length of time in 
fixation with 3α,5α-THP immunoreactivity to detect potential confounding factors. All 
values were reported as mean ± standard error of mean (SEM) and significance were defined 
at p ≤ 0.05. A single investigator conducted all IHC and statistical analysis.
Results
Human Midbrain Samples
ANOVA analyses indicated no significant differences in age (F(1,63)= 0.28, p= 0.98), 
postmortem interval (PMI) (F(1,63)= 1.58, p= 0.31) or time in fixation (TIF) (F(1,63)= 0.52, 
p= 0.94) between controls and AUD patients in the VTA and SNM regions. There were no 
significant correlations between in 3α,5α-THP immunoreactivity and age, PMI, or TIF of 
subjects in the VTA and SNM regions (Pearson's test, p>0.05). It is notable that the average 
3α,5α-THP immunoreactivity was 5.8 times higher in the SNM region than the VTA region 
(p<0.0001).
3α,5α-THP Levels in Human VTA of AUD Patients Differed from Control Subjects
Cellular 3α,5α-THP levels between AUD patients and control subjects were examined in the 
VTA. There was a 23.2±9% increase in 3α,5α-THP immunoreactivity of AUD patients 
compared to controls (Student's t test, t(63)= 2.517, p= 0.014, Figure 1-D) in the VTA. 
However, correlations between 3α,5α-THP immunoreactivity and total lifetime alcohol 
drinking (kg) (r = −0.06, n= 38, p= 0.74), mean daily alcohol consumption (gram) (r = 
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−0.10, n= 36, p= 0.55), or total drinking years (r= 0.17, n=38, p=0.29) were not significant 
among AUD patients in the VTA by Pearson tests.
Next, the effects of AUD were evaluated independently in each sex, such that male or female 
AUD patients were directly compared to their respective same sex controls, after the data 
was normalized to % control values. Male AUD patients had 31.0±11% higher 3α,5α-THP 
levels than male controls in the VTA (Student's t test, t(33)=2.87, p<0.01, Figure 1-F), but 
similar differences in female controls and AUD patients (21.8±13%) did not reach 
significance (p>0.05) in the VTA. To examine the possibility of sex differences, male and 
female subjects were reexamined in the same IHC assay, comparing actual pixel density 
levels of 3α,5α-THP and the related data was transformed as % of male controls (Figure 1-
G). In this experiment, there was no difference in 3α,5α-THP immunoreactivity between 
male and female subjects (p>0.05). Two-way ANOVA with sex and AUD as factors 
indicated no interaction between the effects of AUD and sex on 3α,5α-THP 
immunoreactivity (F(1, 56) = 0.12, p= 0.73). The main effect analysis showed that AUD 
produced an increase in 3α,5α-THP immunoreactivity (F(1, 56) = 4.85, p= 0.032), while sex 
had no significant effect on 3α,5α-THP immunoreactivity (p= 0.13) in the VTA.
Sex-Specific Effect of AUD on 3α,5α-THP Immunoreactivity in Substantia Nigra Pars 
Medialis
No significant difference in 3α,5α-THP immunoreactivity of AUD patients compared to 
controls was found in the SNM (Student's t test, t(61)=1.506, p=0.14, Figure 2-D). Among 
AUD patients, correlations between 3α,5α-THP immunoreactivity and total lifetime alcohol 
drinking (kg) (r = 0.09, n =36, p= 0.64), mean daily alcohol consumption (gram) (r =0.17, 
n=36, p = 0.32), or total drinking years (r=0.05, n=36, p=0.77) were not significant in the 
SNM by Pearson tests.
Sex-specific effects of AUD were examined as described above. First, the effects of AUD 
were evaluated independently in each sex. Male AUD patients had 29.6±10% higher 3α,5α-
THP levels than male controls in the SNM (Student's t test, t(34)=2.967, p<0.01, Figure 2-E), 
while there was no significant difference between female AUD patients and female controls 
(p>0.05), despite the observation that female AUD patients averaged 16.7±9% lower 3α,5α-
THP levels than female controls in the SNM. We also compared actual pixel density levels 
of 3α,5α-THP between males and females in a separate IHC experiment (Figure 2-G). 
Female control subjects had 51.1±18% higher 3α,5α-THP immunoreactivity than male 
controls in the SNM (p<0.05).
There was a statistically significant interaction between the effects of AUD and sex on 3α,
5α-THP immunoreactivity (F(1, 55) = 7.04, p= 0.01) and the main effect analysis showed that 
sex had a significant effect on 3α,5α-THP immunoreactivity (F(1, 55) = 4.48, p= 0.038). We 
conclude 3α,5α-THP levels increased only in the male AUD patients compared to male 
controls and sex is an influencing factor on 3α,5α-THP levels in the SNM. .
Potential confounding factors related to the 51.1±18% increase in the female controls 
compared to male controls in the SNM were further explored. However, we found no 
significant difference in age, PMI, TIF, brain pH, mean daily alcohol consumption (gram), 
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lifetime alcohol drinking (kg), total drinking years, and pack-years smoking history between 
female controls vs. male controls (p>0.05).
The Effect of Comorbidity with Liver Cirrhosis on 3α,5α-THP Immunoreactivity in AUD
The subjects were compared based on the liver pathology as AUD with cirrhosis (n=21), 
AUD with no cirrhosis (n=17), and controls (n=27) (Figure 1-E) by ANOVA and post-hoc 
analyses in the VTA. There was 24.5±10% increase in 3α,5α-THP immunostaining for 
AUD subjects with cirrhosis compared to controls (F(2,62)=3.15, p<0.05). The difference 
between AUD subjects with no cirrhosis and controls was not significant despite the 
observation that non-cirrhotic AUD patients had 21.6±11% higher 3α,5α-THP levels in the 
VTA (p>0.05). There was no difference between 3α,5α-THP immunoreactivity of cirrhotic 
AUD patients and non-cirrhotic AUD patients (p>0.05) in the VTA. Thus, 3α,5α-THP levels 
in the VTA of the non-cirrhotic and cirrhotic AUD patients were likely similarly affected.
Since the effects of AUD on 3α,5α-THP immunoreactivity in SNM were only observed in 
the male subjects, the role of liver pathology was examined in three groups of male subjects: 
AUD with cirrhosis (n=13), AUD with no cirrhosis (n=14), and controls (n=10) (Figure 2-F). 
There was a 31.2±9% increase in 3α,5α-THP immunoreactivity of male non-cirrhotic AUD 
patients compared to the male controls (F(2,34)=4.76, p= 0.02). The difference between male 
AUD with cirrhosis and male controls was not significant despite the observation that male 
cirrhotic-AUD patients had 21.8±10% higher 3α,5α-THP levels in the SNM. There was no 
difference between 3α,5α-THP immunoreactivity of cirrhotic AUD patients and non-
cirrhotic AUD patients (p>0.05) in the SNM. Thus, 3α,5α-THP levels in the SNM of the 
non-cirrhotic and cirrhotic AUD patients were likely affected similarly.
We examined the role of smoking history in all subjects, since 66% of the controls and 75% 
of the AUD patients were reported as smokers. Average cigarette smoking was 33.3±3 pack-
years in all cases with no significant difference between controls and AUD patients (p= 
0.35). There was also no significant correlation between pack-years smoking history and 3α,
5α-THP immunoreactivity in either VTA or SNM regions (Pearson's test, p>0.05).
3α,5α-THP co-localizes with TH and NeuN in the VTA and SNM
To identify cell types in which 3α,5α-THP is localized in the VTA and SNM, we conducted 
double immunofluorescent labeling of 3α,5α-THP with NeuN and TH in human control 
subjects not included in the experiments above. We found that 3α,5α-THP shows a very 
high rate of co-localization with NeuN in the VTA and SNM (Figure 3 A and C). This 
finding suggests that 3α,5α-THP is primarily localized in neurons in the VTA and SNM. We 
also observed that 3α,5α-THP was localized in TH positive neurons to a large extent in the 
VTA and SNM (Figure 3 B and D) suggesting that 3α,5α-THP is largely, but not 
exclusively, found in the dopaminergic neurons of the VTA and SNM.
Time in fixation (TIF) and Age were Negatively Related to 3α,5α-THP Immunoreactivity in 
Human Amygdala Regions
ANOVA analyses indicated no significant differences in PMI (F(1,34)= 0.017, p=0.99), or age 
(F(1,34)= 0.004, p=0.99) or TIF (F(1,34)= 0.65, p=0.88) between controls and AUD patients in 
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the lateral and basolateral amygdala. Pearson's test was used to assess correlations between 
in 3α,5α-THP immunoreactivity and PMI (days), age (year), or TIF (days) in the lateral and 
basolateral amygdala. There was no correlation between in 3α,5α-THP immunoreactivity 
and PMI in lateral or basolateral amygdala (p>0.05). However, 3α,5α-THP levels were 
negatively related to the age of subjects in lateral amygdala (r = −0.37, p=0.025, n=36) and 
basolateral amygdala (r = −0.49, p=0.0025, n=36) (Figure 4-D and 4-E). 3α,5α-THP levels 
were also negatively related to the time in fixation of subjects in lateral amygdala (r = −0.41, 
p=0.013, n=36) and basolateral amygdala (r = −0.36, p=0.032, n=36) (Figure 4-G and 4-F). 
These factors confound the analysis of potential differences between controls and AUD 
patients. Nonetheless, we analyzed the lateral and basolateral amygdala regions to compare 
cellular 3α,5α-THP immunoreactivity between controls and AUD patients. There was no 
significant difference in 3α,5α-THP immunoreactivity between controls and AUD in the 
lateral amygdala (t(31)=0.23, p=0.82, Figure 4-H) and basolateral amygdala (t(31)=0.22, 
p=0.83, Figure 4-I).
Discussion
The present set of experiments show that cellular 3α,5α-THP levels are 23.2±9% higher in 
the VTA of human AUD patients compared to the age matched controls. The difference in 
3α,5α-THP levels in the VTA of AUD patients was driven by males. There was not a 
significant difference among female subjects, although the absolute difference was similar to 
male subjects. The lack of effect in females may be due to higher variability in 3α,5α-THP 
levels of female control subjects or the smaller sample size. Unfortunately, additional 
samples were not available for analysis. Likewise, 3α,5α-THP levels were significantly 
higher in the SNM of male AUD patients compared to the male controls, while there was no 
difference among female AUD patients compared to female controls.
Dual label confocal microscopy revealed that cellular 3α,5α-THP expression was primarily 
localized in TH positive dopaminergic neurons in the VTA and SNM. This finding is 
consistent with our previous observation in rat brain (Cook et al., 2014b). In general, 
increases in cellular 3α,5α-THP levels are associated with an enhancement in GABAergic 
tone, resulting in a reduction in the neuronal excitability (Akk et al., 2005, Sanna et al., 
2004). VTA dopaminergic activity increases after acute ethanol administration that is 
associated with the rewarding effect of ethanol and increased dopamine release within 
nucleus accumbens. Furthermore, withdrawal from chronic ethanol exposure reverses this 
effect and leads to a decrease in the activity of VTA dopaminergic neurons (Morikawa and 
Morrisett, 2010) that could be related to an increase in 3α,5α-THP levels in VTA dopamine 
neurons. It is well known that the last exposure time to ethanol is an important determinant 
of the activity of VTA dopaminergic neurons. Unfortunately, no information was available 
related to the interval between the last exposure to alcohol and the death of the subjects. 
Thus, we are unable to report the alcohol status immediately before death.
However, since the most common cause of death was chronic cardio-respiratory system 
failure, not accident or suicide, variations in drinking before death were likely due to 
hospitalizations or disease related impairments. Nonetheless, the increase in 3α,5α-THP 
levels may contribute to adaptive responses in the dopaminergic VTA neurons after chronic 
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ethanol exposure. However, we cannot eliminate the probability that an increase in local 3α,
5α-THP levels also affects the GABAergic and glutamatergic neurons in the VTA. While 
little is known about the VTA micro-circuitry connections and sub-regions in human brain, 
further experimentation will be needed to understand how local 3α,5α-THP alterations in 
the VTA affect human mesolimbic activity and drinking behavior.
These results differ from studies in animal models of AUD. We have previously shown a 
decrease in 3α,5α-THP levels in the VTA of C57BL/6J mice after chronic intermittent 
ethanol exposure and withdrawal (Maldonado-Devincci et al., 2014). In that study, we 
examined coronal sections of VTA at the level of bregma −3.08, while the human study 
examined VTA in the transverse plane at the level of the red nucleus. Therefore, we cannot 
rule out the possibility that differences in the VTA subregions investigated contribute to the 
different results in the two studies. Other studies reported a similar increase in whole brain 
3α,5α-THP levels after voluntary ethanol consumption for 17 days in C57BL/6J mice (Finn 
et al., 2004), decreases in cortical and hippocampal 3α,5α-THP concentrations following 
chronic EtOH exposure in rats (Janis et al., 1998, Cagetti et al., 2004), and decreases in 
amygdala subregions of non-human primates after one year of ethanol consumption (Beattie 
et al., 2015). Possible explanations for the discrepancy between human AUD patients and 
rodent models of chronic alcohol exposure include influences such as the age of the subjects 
(humans: age 57; rodents: young adults), duration of alcohol exposure (humans: ~30 yr; 
rodents: 2-6 weeks), and co-occurring liver disease in humans that is quite rare in rodent 
models of chronic alcohol exposure (Tsukamoto et al., 1995). Furthermore, studies in rat 
models used radioimmunoassay (Janis et al., 1998) or gas chromatography-mass 
spectroscopy (Cagetti et al., 2004) to measure 3α,5α-THP levels, while levels in human 
VTA and SNM were determined by immunohistochemistry. Another notable difference in 
the present study is the presence of ethanol exposure in human control subjects. Social 
drinkers who consumed 1-2 drinks per day were analyzed as control subjects in this study. 
On the other hand, alcohol naïve animals were used as the control group in all rodent 
studies. Therefore, differences between animal models and human studies should be taken 
into consideration.
Increases in 3α,5α-THP levels in the VTA and partially in the SNM (only among male 
subjects) are concordant with a recent post-mortem brain study examining steroid levels in 
human AUD patients. In the study, pregnenolone (a precursor to 3α,5α-THP) and 
dehydroepiandrosterone (a precursor of the GABAergic neuroactive steroid, androsterone) 
levels were higher in most limbic brain regions in AUD patients, compared to non-alcoholic 
controls (Karkkainen et al., 2016). Together, these findings may indicate a global increase in 
neurosteroid content in the brains of human AUD patients. Further studies are needed to test 
this hypothesis.
Potential cross-reactivity of anti-3α,5α-THP antibody with other neurosteroids should be 
taken into consideration. We have previously observed a 9±1.6% cross reactivity of anti-3α,
5α-THP antibody with pregnenolone (Cook et al., 2014a) which may contribute to the 
similar outcomes with the recent post-mortem human study (Karkkainen et al., 2016). Cross-
reactivities between anti-3α,5α-THP antibody and other neurosteroids such as 3α-HP or 3α,
5β-THP has been also discussed in the previous work (Cook et al., 2014a). Additionally in 
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this study, we detected negligible cross-reactivity between anti-3α,5α-THP antibody with 
3α-reduced androstanes (see Materials and Methods) suggesting that the interactions with 
anti-3α,5α-THP and 3α-reduced androstanes are minimal.
The difference in the ages of human subjects vs. rodent studies deserves further 
consideration. We examined human AUD patients at an average age of 57, which would 
correspond to an 18+ month old rat (Sengupta, 2013). In comparison, studies investigating 
the effect of chronic ethanol exposure on brain 3α,5α-THP levels have primarily been 
conducted in 2 to 4 month old young adult rodents (Janis et al., 1998, Cagetti et al., 2004, 
Maldonado-Devincci et al., 2014) leaving gaps in our knowledge in the effect of alcohol on 
the neurosteroid levels in rodents vs. humans. Aged humans show differential GABAA 
receptor subunit expression (Kanaumi et al., 2006), have higher physiological sensitivity to 
alcohol (Menninger, 2002), and are more susceptible to the deficits associated with chronic 
AUD (Pfefferbaum et al., 1992). Further, aged animals show greater ethanol-induced 
memory impairment and exhibit fewer withdrawal symptoms compared to adult animals 
(Novier et al., 2016) suggesting that aged adult individuals have unique responses to chronic 
ethanol exposure. In this study, we also show that 3α,5α-THP concentrations are negatively 
correlated with age in amygdala regions, but not in the VTA and SNM regions. These 
finding may suggest that the 3α,5α-THP content in various brain areas are affected by the 
aging process differently.
Patients with a diagnosis for psychiatric, neurologic and neurodegenerative conditions were 
excluded from the study to eliminate confounding factors. However, AUD causes secondary 
medical conditions, including alcoholic liver disease. Cirrhosis is the final phase of alcoholic 
liver disease, characterized by irreversible hepatic tissue transformation. In our study, more 
than half of the AUD patients were complicated with liver cirrhosis, while the remaining 
AUD patients had milder and reversible manifestations of liver disease such as congestion or 
steatosis. Only 5% of the AUD patients showed no signs of liver disease. In our study, we 
found no significant difference in 3α,5α-THP brain levels of non-cirrhotic AUD patients 
compared to cirrhotic alcoholics, suggesting that AUD is the main factor in the observed 
increase in AUD patients. However, others have reported that in the majority of male 
individuals with alcoholic fatty liver change and alcoholic cirrhosis, 3α,5α-THP precursor 
progesterone plasma levels were above the upper limit of normal plasma progesterone 
concentration (Farthing et al., 1982). Moreover, increase in plasma 3α,5α-THP 
concentrations have been also shown in non-alcoholic liver injuries (Ahboucha et al., 2008). 
Besides, 3α,5α-THP is known to readily cross the blood brain barrier (Zhu et al., 2001) and 
3α,5α-THP precursors are metabolized in the liver (Stanczyk, 2003). 3α,5α-THP levels 
were also significantly higher in the brain extracts from hepatic encephalopathy patients who 
died in hepatic coma (Ahboucha et al., 2006), but no difference was found between patients 
with uncomplicated liver disease and controls. Therefore, we conclude that 3α,5α-THP 
elevations in VTA are not substantially moderated by liver disease.
In the SNM, female control subjects averaged 51±18% higher brain 3α,5α-THP levels than 
male control subjects, but this effect was not observed in the VTA. In this study, we also 
compared VTA and SNM 3α,5α-THP levels between pre-menopausal women (<48yr) 
versus post-menopausal women (>55yr) by grouping them according to adjusted median age 
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of natural menopause (51.7yr) in the Australian population (Do et al., 1998). However, 
comparisons of these two age groups were not significantly different in any brain region 
studied (data not shown). Other human studies show that average brain progesterone and 3α,
5α-THP concentrations were significantly higher in the fertile women in the luteal phase of 
the menstrual cycle compared to their postmenopausal controls (Bixo et al., 1997), 
suggesting that females have higher basal 3α,5α-THP levels in the brain. Together, these 
findings may suggest that the basal 3α,5α-THP content in female brain is likely higher than 
male brain, but different brain areas may show greater sensitivity to sex-related effects.
Studies in amygdala sections of human AUD patients were confounded by the effects of 
fixation time in formalin. It is well know that immunohistochemistry is greatly influenced by 
the fixation time in formalin (Grillo et al., 2015). Accordingly, we found that 3α,5α-THP 
levels in the lateral and basolateral amygdala are negatively correlated with the fixation time 
in formalin. Average length of fixation time for human amygdala samples was more than 6 
years, producing a challenge to measure 3α,5α-THP levels in amygdala regions. We also 
observed a negative correlation between age and 3α,5α-THP levels that may also confound 
the analysis of potential differences between control and AUD patients. On the other hand, 
VTA and SNM samples were fixed in formalin for less than a month on average, and there 
was no correlation between 3α,5α-THP levels and fixation time in the VTA or SNM. 
Therefore, antigenic epitopes in the VTA and SNM regions may be relatively preserved from 
any masking effect of formalin.
The observation that 3α,5α-THP levels were decreased with aging in amygdala, but not 
VTA or SNM, of humans subjects suggests regional variation in regulation of 3α,5α-THP 
synthesis or degradation. Animal studies examining the effect of aging on 3α,5α-THP brain 
levels have yielded inconsistent results. Brain 3α,5α-THP content showed a significant 
progressive decrease with age in Wistar rats (Bernardi et al., 1998) but showed no difference 
between 2 month old and 18 month old Sprague Dawley rats (Barbaccia et al., 1998). A 
similar decline has been observed in several rat brain regions that could be linked to sleep 
cycle alterations and cognitive impairment in aged rat populations (George et al., 2010). 
Taken together, 3α,5α-THP levels may show a region specific decrease in the brain with age 
that could contribute to physiological aging or age-related pathological conditions. Thus, 
future studies are required to expand our understanding of age-related differences.
The study had several limitations. First, relative values of immunoreactivity were determined 
via measuring the pixel density within a prescribed field over pre-established baseline levels. 
Therefore, values are relative and expressed as percent control or average pixel density, 
making it impossible to compare absolute 3α,5α-THP levels in the brain regions. Second, 
other GABAergic neuroactive steroid levels should be measured to understand the complete 
neurosteroid pattern in post-mortem human brain regions. Moreover, highly relevant brain 
regions including nucleus accumbens, hippocampus, prefrontal cortex, and anterior cingulate 
cortex should be investigated in order to compare data with rodent studies that examined 
more regions.
Alterations in 3α,5α-THP levels may contribute to adaptive responses in VTA neurons or 
the elevation of 3α,5α-THP levels may represent a biomarker of alcohol abuse. The 
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differences between animal models and human studies should be considered to determine 
the physiological significance of elevated 3α,5α-THP levels in humans. In conclusion, 
cellular 3α,5α-THP levels in the VTA are increased in human AUD patients that are likely 
independent of sex and liver disease. Further studies are needed to determine the 
physiological significance of elevated 3α,5α-THP levels in humans.
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Figure 1-A is a schematic diagram of the intermediate midbrain in the rostro-caudal 
transverse axis. Figures 1-B and C show representative photomicrographs (10X) of 3α,5α-
THP immunostaining in the VTA of control and AUD patients. The red box in Figure 1-A 
shows the VTA region that is represented in the photos. Figure 1-D shows the comparison 
between controls and AUD patients. There was a 23.2±9% increase in 3α,5α-THP 
immunoreactivity of AUD patients compared to controls (p=0.014) in the VTA. Figure 1-E 
shows the comparison based on the liver pathology as AUD with cirrhosis, AUD with no 
cirrhosis, and controls in the VTA. There was 24.5±10% increase in 3α,5α-THP 
immunostaining from AUD subjects with cirrhosis compared to controls (p<0.05). Figure 1-
F shows the comparison between controls and AUD patients independently for each sex. 
Male AUD patients had 31.0±11% higher 3α,5α-THP levels than male controls in the VTA 
(p<0.01) after the data was normalized to % of control values by sex. Figure 1-G shows the 
evaluation of the sex-related differences by comparing actual pixel density levels of 3α,5α-
THP between males and females in the VTA. There was no difference in 3α,5α-THP 
immunostaining between male and female subjects (p>0.05) in the VTA. ANOVA analysis 
indicated no significant interaction between the effects of AUD and sex on 3α,5α-THP 
immunoreactivity (p=0.73) and the main effect analysis showed that AUD produced an 
increase in 3α,5α-THP immunoreactivity (p=0.032) in the VTA.
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Figure 2-A is a schematic diagram of the intermediate midbrain in the rostro-caudal 
transverse axis. Figures 2-B and C show representative photomicrographs (10X) of 3α,5α-
THP immunostaining in substantia nigra pars medialis (SNM) of controls and AUD patients. 
The red box in Figure 2-A shows the SNM region that is represented in the photos. Figure 2-
D shows the comparison between controls and AUD patients. No significant difference in 
3α,5α-THP immunoreactivity of AUD patients compared to controls was found in the SNM 
(p=0.14). Figure 2-E shows the comparison between controls and alcoholic subjects 
independently for each sex after the data was normalized to % of control values. Male AUD 
patients had 29.6±10% higher 3α,5α-THP levels than male controls in the SNM (p<0.01). 
Figure 2-G shows the evaluation of the sex-related differences by comparing actual pixel 
density levels of 3α,5α-THP between males and females in the SNM. Female control 
subjects had 51.1±18% higher 3α,5α-THP immunoreactivity than male controls in the SNM 
(p<0.05). There was a statistically significant interaction between the effects of AUD and 
sex on 3α,5α-THP immunoreactivity (p=0.01) and the main effect analysis showed that sex 
had a significant effect on 3α,5α-THP immunoreactivity (p=0.038). Figure 2-F shows the 
comparison based on the liver pathology in the male subjects as AUD with cirrhosis, AUD 
with no cirrhosis, and controls in the SNM. There was a 31.2±9% increase in 3α,5α-THP 
immunoreactivity of male non-cirrhotic AUD patients compared to the male controls 
(p=0.02).
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Dual immunolabeling with NeuN (red) or TH (red) with 3α,5α-THP (green) in the VTA (A 
and B). Dual immunolabeling with NeuN (red) or TH (red) with 3α,5α-THP (green) in the 
SNM (C and D). Confocal scanning showed that 3α,5α-THP co-localizes with NeuN 
positive and TH positive neurons in the VTA and SNM of postmortem human brain sections.
Hasirci et al. Page 20














Figure 4-A is a schematic diagram of the amygdala in the coronal plane. Figures 4-B and C 
show representative photomicrographs (10X) of 3α,5α-THP immunostaining in the lateral 
and basolateral amygdala. The red boxes in Figure 4-A show the regions that are represented 
in the photos. Figure 4-D and 4-E indicate that 3α,5α-THP levels were negatively related to 
the age of subjects in lateral amygdala (Pearson's r value= −0.37, p=0.025, n=36) and 
basolateral amygdala (Pearson's r value= −0.49, p=0.0025, n=36). Figure 4-F and 4-G show 
that 3α,5α-THP levels were negatively related to the time in fixation of samples in lateral 
amygdala (Pearson's r value= −0.41, p=0.013, n=36) and basolateral amygdala (Pearson's r 
value= −0.36, p=0.032, n=36).
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Table 1
Patient Characteristics of Human Postmortem Brains
Brain Region:
Ventral Tegmental Area Lateral Amygdala
Substantia Nigra Pars Medialis Basolateral Amygdala
Sex Male Female Male
Group Control AUD Control AUD Control AUD
Number of Subjects 12 24 15 14 13 23
Age of Death 56.6±3 56.0±2 56.5±3 59.8±3 57.8±4 56.7±2
Mean Alcohol Consumption (g/day) 15.3±5 234±30 8.8±3 206±25 15.9±5 212±29
Total Drinking Years 27.9±6 32.0±1 25.9±6 31.9±3 28.6±5 32.3±2
Alcohol lifetime use (kg) 191±90 2650±342 114±39 2253±370 228±96 2449±297
Postmortem Interval (hours) 32.9±3 35.0±3 28.9±3 32.5±5 32.4±4 36.9±3
Time In Fixation (days) 25.4±2 24.8±2 20.5±1 22.9±1 2479±362 2307±270
Values were reported as mean ± standard error of mean (SEM)
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